Salute e Benessere

EPIDIOLEX Continues to Lead the Way in Cannabinoid-Based Epilepsy Treatment |…

Jazz Pharmaceuticals' EPIDIOLEX (cannabidiol) Overview Jazz Pharmaceuticals' EPIDIOLEX (cannabidiol) Overview EPIDIOLEX (formerly known as GWP42003-P and marketed as EPIDYOLEX inEurope ) is the first plant-based, prescription cannabis-derived oral medication developed by GW Pharmaceuticals. It represents a new category of antiepileptic drugs with a unique mechanism of action. The active compound, cannabidiol (CBD), is a naturally occurring cannabinoid found in theCannabis sativa L...
PR Newswire
01/05/2025

In Vitro Diagnostics: Technologies Transforming Global Healthcare Markets

This report analyzes in vitro diagnostic (IVD) technologies and devices used in hospitals and point-of-care (POC) settings, focusing on market trends, drivers, opportunities, and competitive intelligence. It segments the market by technology, application, end user, and region, with forecasts through 2029. This report analyzes in vitro diagnostic (IVD) technologies and devices used in hospitals and point-of-care (POC) settings, focusing on market trends, drivers, opportunities, and competitive...
PR Newswire
01/05/2025

Home Fragrance Charms the 137th Canton Fair

Shanghai Outstanding Industry Co., Ltd., a fragrance-focused enterprise, exemplifies this trend. The company's CEO Michael Lu noted that they launched 12 new series this session, highlighting the importance of research and development. Product design also emphasizes aesthetics to enhance home spaces. Lu said that consumers increasingly value "organic," "natural," and "environmentally friendly" fragrances, prompting the company to introduce the first carbon-neutral…
PR Newswire
01/05/2025

New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty

VANCOUVER, BC, May 1, 2025 /PRNewswire/ --Equity InsiderNews Commentary – Optimism in the field of oncology is on the rise, thanks to the National Institutes of Health's latest annual report, which showed a steady decline in cancer death rates. However, incidence rates and diagnoses are on the rise, meaning the need for better treatment and earlier screening remains. With potential NIHbudget reductions under discussion and new projections indicating that drug tariffs could raise treatment costs…
PR Newswire
01/05/2025

Image-guided Navigation Market worth US$3,912.5 million by 2030 with 9.0% CAGR |…

Browse in-depth TOC on "Image-guided Navigation Market"300 - Tables100 - Figures400 - Pages Browse in-depth TOC on "Image-guided Navigation Market" 300 - Tables 100 - Figures 400 - Pages By Based on product type,the workstations & software segment is projected to dominate the market, primarily due to its pivotal role in the integration of advanced imaging modalities with real-time surgical navigation systems. Unlike hardware solutions, software offers seamless...
PR Newswire
01/05/2025

Resmed Acquires VirtuOx

Acquisition supports Resmed's growth in virtual care, expands access to diagnosis, and enhances the digital experience for patients and providers The acquisition reflects Resmed's commitment to improving the way care is delivered—by making it more accessible, more coordinated, and more patient friendly. With VirtuOx's at-home diagnostic services, Resmed will be better positioned to support patients earlier in their journey and help healthcare providers and homecare companies deliver care in...
Nasdaq GlobeNewswire
01/05/2025

PureHealth Reports USD 137.6 Million Net Profit and USD 308.5 Million EBITDA for…

Shaista Asif, Group Chief Executive Officer at PureHealth, commented, "PureHealth's first quarter results reflect the solid growth witnessed across all core segments. The Group's results for the period came on the back of strong patient volume increases across our hospital network, both locally and internationally, and continued momentum in our insurance division with high renewal rates and expansion into new markets. Our strong operational execution, transformations of the assets, and the…
PR Newswire
01/05/2025

FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic…

LONDON and NEW YORK, May01, 2025(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular condition associated with chronic and often severe pain but without an FDA-approved therapy, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to urcosimod for the treatment of neuropathic corneal pain (NCP).Fast Track...
Nasdaq GlobeNewswire
01/05/2025

Coloplast A/S Revised guidance for FY 2024/25

Coloplast revises financial guidance for FY 2024/25 and pre-announces H1 2024/25 key financial figures Coloplast revises the guidance on organic growth and EBIT margin before special items for FY 2024/25. The organic growth is now expected to be around 7%, from previously 8-9%. The EBIT margin before special items is now expected to be 27-28%, from previously around 28%. Key financial figures and developments in Q2:Group organic growth was 6% in Q2. The EBIT margin before special...
Nasdaq GlobeNewswire
01/05/2025

EnChannel Medical Raises $82.2M in Oversubscribed Series-B Financing to Advance…

"EnChannel's platform integrates full-chamber action-potential mapping with pulsed-field ablation to address long-standing unmet needs in atrial fibrillation treatment," said Jun Feng, CEO of EnChannel Medical. "We're grateful for the strong support from new and returning investors and encouraged by early clinical data from our ongoing studies. Key results were presented at the Heart Rhythm Society Meeting in San Diego, held April 24-27." "EnChannel's platform integrates…
PR Newswire
01/05/2025

Doceree welcomes Karima Sharif as SVP - Strategic Accounts, to strengthen global…

A powerhouse in healthcare marketing, Karima is known as the "Fresh Princess of Media." With an unmatched depth of experience across omnichannel strategy, multicultural and inclusive marketing, customer and data segmentation, and full-funnel media execution across both DTC and HCP audiences, she has helped shape the marketing journeys of 100+ pharmaceutical and medical device brands across various therapeutic categories. Her career is highlighted by the impact she's made at…
PR Newswire
01/05/2025

AB Science will publish its 2024 annual financial report on May 9, 2025

PRESS RELEASETHE COMPANY WILL PUBLISH ITS 2024 ANNUAL FINANCIAL REPORT ON 9 MAY 2025Paris, May 1 st2025, 10am CETAB Science SA(Euronext - FR0010557264 - AB) today announced that it has postponed the publication of its 2024 annual financial report, initially scheduled for 30 April 2025, to give the auditors time to complete their audit work.The Company will publish its 2024 annual financial report no later than Friday May 9, 2025, after trading. About AB Science...
Nasdaq GlobeNewswire
01/05/2025

Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming…

/ ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced upcoming presentations highlighting its innovative late-stage pipeline at Eyecelerator 2025, the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and the Retina World Congress (RWC).The presentation of the DME AWARE Delphi Study interim results will highlight key areas of...
Nasdaq GlobeNewswire
01/05/2025

S&E bio Receives Korea's First Approval for Exosome-Based Therapy Clinical Trial

The approval followed successful resolution of Chemistry, Manufacturing, and Controls (CMC) issues, as well as demonstration of therapeutic efficacy not only in rodent models but also in non-human primates, which better reflect human stroke pathology. Long-term safety was also confirmed. The approval followed successful resolution of Chemistry, Manufacturing, and Controls (CMC) issues, as well as demonstration of therapeutic efficacy not only in rodent models but also in non-human primates,...
PR Newswire
01/05/2025

Blue Earth Therapeutics initiates Phase 2 Clinical Trial evaluating the efficacy…

Loading doses will be delivered by either a) giving a higher dose in the first two treatment cycles, or b) shortening the time between administration of the first three doses to three weeks from the usual six weeks. The study is also designed to test the clinical benefit of administration of high total doses of administered radioactivity, up to 60GBq. The Phase 1 data confirmed a high ratio of uptake in tumor tissues vs. uptake in healthy tissues such as kidneys and salivary glands1. Loading...
PR Newswire
01/05/2025

Roquette Completes the Acquisition of IFF Pharma Solutions

Roquette Completes the Acquisition of IFF Pharma SolutionsLille, May 1, 2025 –Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for the health and nutrition sectors, announces the successful completion of its acquisition of IFF Pharma Solutions. This strategic milestone marks a significant step forward in its ambition to become a leader in support of the global pharma markets.With this acquisition, and following that of Qualicaps in 2023, Roquette...
Nasdaq GlobeNewswire
01/05/2025

Rediscovering Quality Home Life Through Nature-Inspired Design at 137th Canton…

The booth of Shanghai Dandou Home Furnishing Co., Ltd. exudes the rich texture and warmth of aged timber. Specializing in home furniture and decoration, Dandou embraces a philosophy of revitalizing recycled wood, utilizing wood salvaged from historic European and Chinese structures to produce handcrafted and vintage-style furniture. The booth of Shanghai Dandou Home Furnishing Co., Ltd. exudes the rich texture and warmth of aged timber. Specializing in home furniture and decoration, Dandou...
PR Newswire
01/05/2025

Roche's Susvimo FDA Approval Marks New Era in Diabetic Macular Edema Treatment…

The primary treatment for DME includes intravitreal injections, where the eye is numbed with drops before injecting medication directly into the vitreous humor. Common anti-VEGF drugs used include AVASTIN, EYLEA, and LUCENTIS. Additionally, corticosteroids are beneficial in cases of DME linked to inflammatory eye conditions and can be delivered via eye drops, oral tablets, or periocular injections to help reduce inflammation. The US FDA approved sustained-release corticosteroid implants for more…
PR Newswire
30/04/2025

Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare…

About Jazz PharmaceuticalsJazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and…
PR Newswire
30/04/2025

Combined General Meeting of May 22, 2025 - Availability of the preparatory…

Daix (France), New York City (New York, United States), April 30, 2025– Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined...
Nasdaq GlobeNewswire
30/04/2025

Statement of total voting rights and shares forming the company's share capital…

Article R. 22-10-23 of the French Commercial CodeMarket: Euronext Paris ISIN code / Mnemo: FR0013233012 / IVA Web site:www.inventivapharma.com DateNumber of shares outstandingTotal voting rights, gross(1) Total voting rights, net(2) April 11, 202595,662,391108,635,435108,574,827The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General...
Nasdaq GlobeNewswire
30/04/2025

DBV Technologies Reports First Quarter 2025 Financial Results

DBV Technologies Reports First Quarter 2025 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today reported financial results for the First Quarter of 2025. The quarterly and three months financial statements were approved by the Board of Directors on April 30, 2025. Financial Highlights for the First Quarter Ended March 31, 2025 The Company's interim condensed...
Nasdaq GlobeNewswire
30/04/2025

Fluorescence Microscopy Market to Reach $1.3 Billion by 2029

This report covers product types such as upright and inverted microscopes and segments the market by illumination method, component, technology, and end-use. It assesses current market status, forecasts growth for the next six years, and analyzes market drivers, restraints, and opportunities. This report covers product types such as upright and inverted microscopes and segments the market by illumination method, component, technology, and end-use. It assesses current market status, forecasts...
PR Newswire
30/04/2025

Navamedic ASA: Annual Report 2024

Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail: [email protected] Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail:[email protected] Lars Hjarrand, CFO, Navamedic Mobile: +47 917 62 842 E-mail:[email protected] About Navamedic: Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's quality of life by being a reliable supplier of high-quality prescription, consumer health, and...
PR Newswire
30/04/2025
Altri  Comunicati